International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Amgen Announces New Otezla (Apremilast) Data

New data presented by Amgen at the 2022 AAD Congress reinforced the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis. This announcement follows the recent US Food and Drug Administration (FDA) expanded Otezla label approval which enabled the use of Otezla across all levels of disease severity. Otezla is the first and only oral therapy FDA approved in adult patients with mild, moderate, and severe plaque psoriasis.
Amgen’s Manufacturing is Worldwide Pioneer in Biotechnology
Recent Posts
Lilly Press Release Graphic

Lilly Announces a New, Citrate-Free Formulation of Taltz® (ixekizumab)

Arcutis Press Release Graphic

Arcutis Announces FDA Approval for ZORYVE (Roflumilast) Cream 0.3% for Plaque Psoriasis in Individuals Age 12 and Older


Un Enfoque en Psoriasis: Un Reporte de el Congreso RADLA 2022

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.